Navigation Links
Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
Date:9/19/2013

of the disease provides the greatest opportunity to reap substantial improvements in muscle strength and function, potentially resulting in a lifetime of benefit. ISIS-SMNRx targets the underlying primary cause of SMA, taking advantage of the backup gene, SMN2, present in all SMA patients," said Kathryn J. Swoboda, M.D., professor, department of neurology and director of pediatric motor disorders research program at the University of Utah, School of Medicine.  "Preliminary results from Phase 1 clinical trials reveal a favorable safety profile, and appear to indicate that a single dose of the medication at the higher doses tested to date may result in sustained benefit over many months in some children. Thus, while early, we are excited to continue to work closely with Isis in further studies of ISIS-SMNRx in SMA."

"We are pleased with the progress we are making on ISIS-SMNRx.  Although there was no placebo group, the continuing improvement for up to a year after a single dose observed in this study is encouraging, particularly when considered within the context of the dose response," said B. Lynne Parshall, chief operating officer at Isis.  "Our ongoing Phase 2 program is proceeding well. The 6 mg dose group in our Phase 2 study in infants with Type I SMA has completed dosing.  Based on the safety, pharmacokinetic and pharmacodynamic profile of ISIS-SMNRx we have observed to date, we have amended the infant study to increase the dose from 9 mg to 12 mg dose. We plan to start dosing this cohort soon.  In our Phase 1b/2a multiple-dose study in children with Type II and Type III SMA, we have completed dosing in all three dose cohorts (3 mg, 6 mg and 9 mg), and we are considering adding a 12 mg dose cohort to this study.  The FDA has expressed reservations about increasing the exposure in children with Type II and Type III SMA, and
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Calif. , April 23 PRO-DEX, INC. (Nasdaq: PDEX ) ... period ended March 31, 2010 on Thursday, April 29, 2010 ... , , ... Eastern Time ( 1:30 Pacific Time ) to discuss operating performance for ...
... VIENNA , April 23, 2010 ... progressed to phase II clinical testing.,It may therefore be possible ... 2012. Indeed the start of this efficacy study comes only ... The company,is active in several disease areas and is currently ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 2Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Cardiac Science (Nasdaq: CSCX ), ... rehabilitation, and informatics products, today announced that it ... Association (WBBA) 2009 Invest Northwest CEO and Investor ... in Seattle. Michael Matysik, senior vice president and ...
... Nausea and Vomiting (PONV)CORONA DEL MAR, Calif., March 11 ... patient,s oxygen status known on a beat-by-beat basis. Not ... say that all patients should have this monitor. No ... ASA Newsletter on their web site between 1983 and ...
... Interactive, Inc. was accepted as an affiliate member of ACA International ... as the American Collectors Association. , ... (Vocus) March ... Ave Ste 100, Plantation, FL 33324-3223, was accepted as an affiliate ...
... Corporation with a Scalable, Powerful System in Support of Patient Safety ... ... Francisco, CA (PRWEB) March 11, 2009 -- The Florida Patient Safety ... certified as a Patient Safety Organization (PSO), has chosen Quantros ...
... a toy drive at Build-A-Bear during annual team-building event , ... ... Cydcor , the leading provider of outsourced, face-to-face sales teams, hosted ... annual corporate kick-off meeting. , ,About 70 participating Cydcor ...
... BC Decker Inc, publisher of the acclaimed general surgical reference, ACS ... MD, FACS as the new Editor-in-Chief , ... Philadelphia, ... the acclaimed general surgical reference, ACS Surgery, is honored to announce ...
Cached Medicine News:Health News:Cardiac Science to Present at the Eighth Annual Invest Northwest Conference 2Health News:American Society of Anesthesiologists (ASA) - Myths About 'Never Ending Pursuit of Patient Safety and Satisfaction' Debunked 2Health News:Business Becomes Affiliate Member of International Trade Association 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 3Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 4Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 5Health News:Cydcor Builds Bears and Bonds in Special Charity Event Benefitting Childrens Hospital Los Angeles 2Health News:New Editor, New Vision for ACS Surgery 2Health News:New Editor, New Vision for ACS Surgery 3
... For the qualitative ... falciparum (P.f) antigen and an ... all four species of malaria:plasmodium ... Plasmodium ovale (P.o) and Plasmodium ...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... combines full 0.25 mm pb protection ... drape material that can be placed ... the clinician and the source of ... must be in very close proximity ...
... only insulin pen with a memory. HumaPen MEMOIR records ... doses (including priming doses). You can see exactly when ... MEMOIR, you simply "dial" your dose by turning the ... after initial set-up. If you dial too many units, ...
Medicine Products: